Biological abnormalities of peripheral A2A receptors in a large representation of polyglutamine disorders and Huntington's disease stages

Neurobiology of Disease

Volumn 27, Issue 1, 2007, Pages 36-43

  Varani, K ^b   Bachoud Levi A C ^c,g,h   Mariotti, C ^d   Tarditi, A ^a   Abbracchio, M P ^a   Gasperi, V ^e   Borea, P A ^b   Dolbeau, G ^c,g,h   Gellera, C ^d   Solari, A ^d   Rosser, A ^f   Naji, J ^f   Handley, O ^f   Maccarrone, M ^e   Peschanski, Marc ^c   DiDonato, S ^d   Cattaneo, E ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c ECOLE NORMALE SUPÉRIEURE   (France)

^d DEPARTMENT OF NEUROSURGERY   (Italy)

^e UNIVERSITY OF TERAMO   (Italy)

^f CARDIFF UNIVERSITY   (United Kingdom)

^g INSERM   (France)

^h HENRI MONDOR HOSPITAL   (France)

Author keywords

A2A adenosine receptors; Biomarkers; FRDA; Friedreich ataxia; HD; Huntington's disease; SCA1; SCA2; Spinocerebellar ataxia 1; Spinocerebellar ataxia 2; Triplet repeat disorders

Indexed keywords

ADENOSINE A2A RECEPTOR; POLYGLUTAMINE;

ADULT; AGED; ARTICLE; CELL POPULATION; CONTROLLED STUDY; DEGENERATIVE DISEASE; FEMALE; HUMAN; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MALE; MEMBRANE FLUIDITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; RECEPTOR DENSITY;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; BIOLOGICAL MARKERS; CELL POLARITY; FEMALE; FRIEDREICH ATAXIA; HUMANS; HUNTINGTON DISEASE; LYMPHOCYTES; MALE; MEMBRANE FLUIDITY; MIDDLE AGED; PEPTIDES; RECEPTORS, ADRENERGIC, ALPHA-2; SPINOCEREBELLAR ATAXIAS; TRINUCLEOTIDE REPEATS;

EID: 34250380374     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2007.03.011     Document Type: Article

References (19)

1. Bari M., Battista N., Fezza F., Finazzi-Agrò A., and Maccarrone M. Lipid rafts control signaling of type-1 cannabinoid receptors in neuronal cells. Implications for anandamide-induced apoptosis. J. Biol. Chem. 280 (2005) 12212-12220
2. Bari M., Spagnuolo P., Fezza F., Oddi S., Pasquariello N., Finazzi-Agrò A., and Maccarrone M. Effect of lipid rafts on CB2 receptor signaling and 2-arachidonoylglycerol metabolism in human immune cells. J. Immunol. 177 (2006) 4971-4980
3. Borovecki F., Lovrecic L., Zhou J., Jeong H., Then F., Rosas H.D., Hersch S.M., Hogarth P., Bouzou B., Jensen R.V., and Krainc D. Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 102 31 (2005) 11023-11028
4. Gellera C., Meoni C., Castellotti B., Zappacosta B., Girotti F., Taroni F., and Di Donato S. Errors in Huntington disease diagnostic test caused by trinucleotide deletion in the IT15 gene. Am. J. Hum. Genet. 59 (1996) 475-477
5. International Huntington Association (IHA) and the World Federation of Neurology (WFN) Research Group on Huntington's Chorea. Guidelines for the molecular genetics predictive test in Huntington's disease. Neurology 44 8 (1994) 1533-1536
6. Langbehn D.R., Brinkman R.R., Falush D., Paulsen J.S., and Hayden M.R. International Huntington's disease Collaborative Group. 2004. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin. Genet. 66 1 (2004) 81
7. Maccarrone M., Bladergroen M.R., Rosato N., and Finazzi-Agrò A. Role of lipid peroxidation in electroporation-induced cell permeability. Biochem. Biophys. Res. Commun. 209 (1995) 417-425
8. max) linearly correlates with age at onset and CAG repeat expansion in Huntington's disease patients with predominant chorea. Neurosci. Lett. 393 1 (2006) 27-30
9. Marder K., Zhao H., Myers R.H., Cudkowicz M., Kayson E., Kieburtz K., Orme C., Paulsen J., Penney Jr. J.B., Siemers E., and Shoulson I. Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology 54 (2000) 452-458
10. Parasassi T., Gratton E., Yu W.M., Wilson P., and Levi M. Two-photon fluorescence microscopy of laurdan generalized polarization domains in model and natural membranes. Biophys. J. 72 6 (1997) 2413-2429
11. Shoulson I. Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology 31 10 (1981) 1333-1335
12. 2A receptor signaling in a mouse model of Huntington disease. Neurobiol. Dis. 23 1 (2006) 44-53
13. Trouillas P., Takayanagi T., Hallett M., Currier R.D., Subramony S.H., Wessel K., Bryer A., Diener H.C., Massaquoi S., Gomez C.M., Coutinho P., Ben Hamida M., Campanella G., Filla A., Schut L., Timann D., Honnorat J., Nighoghossian N., and Manyam B. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J. Neurol. Sci. 145 2 (1997) 205-211
14. Trushina E., Singh R.D., Dyer R.B., Cao S., Shah V.H., Parton R.G., Pagano R.E., and McMurray C.T. Mutant huntingtin inhibits clathrin-independent endocytosis and causes accumulation of cholesterol in vitro and in vivo. Hum. Mol. Genet. 15 24 (2006) 3578-3591
15. Valenza M., Rigamonti D., Goffredo D., Zuccato C., Fenu S., Jamot L., Strand A., Tarditi A., Woodman B., Racchi M., Mariotti C., Di Donato S., Corsini A., Bates G., Pruss R., Olson J.M., Sipione S., Tartari M., and Cattaneo E. Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J. Neurosci. 25 (2005) 9932-9939
16. 2A adenosine receptors in human neutrophil membranes. Br. J. Pharmacol. 123 8 (1998) 1723-1731
17. Varani K., Rigamonti D., Sipione S., Camurri A., Borea P.A., Cattabeni F., Abbracchio M.P., and Cattaneo E. Aberrant amplification of A(2A) receptor signaling in striatal cells expressing mutant huntingtin. FASEB J. 15 7 (2001) 12457
18. 2A receptor function in peripheral blood cells in Huntington's disease. FASEB J. 17 (2003) 2148-2150
19. 2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. J. Neurosci. 26 52 (2006) 13548-13555